THE LIVER FUNCTION TEST (TRANSAMINASE ENZYMES AND BILIRUBIN) AND THE KIDNEY FUNCTION TESTS (UREA, CREATININE) ANALYSIS IN MDR-TB DURING TREATMENT

Widaninggar Rahma Putri 1 Indonesia , Havida Widyastuti 1 Indonesia , Dhini Intan Cahyani 1 Indonesia , Wa Ode Hikma Fajar 1 Indonesia
1 Universitas Aisyiyah Yogyakarta
Link Copied!
Published 2026-06-20
Vol. 8 No. 1 (2026) PAGES 109-114
DOI 10.36566/ijhsrd/Vol8.Iss1/370
Views / Downloads 118 82

Background:

Multi Drug Resistance Tuberculosis (MDR-TB) treatment caused side effects such as hepatotoxicity and acute kidney injury (AKI).  Monitoring liver and kidney function in patients during treatment is crucial to prevent complication.

Methods: A retrospective study of 19 patients confirmed MDR-TB in the period 2022-2025. Liver function test (transaminase enzymes and bilirubin) and kidney function test (urea and creatinine) during the first three month of treatment were analyzed.

Results: Statistically, there was no difference in all parameters (p>0.05). Increases in total bilirubin, SGOT, SGPT levels occurred in the third month of TB treatment. While urea and creatinine levels increased in the second and third months.

Conclusion: Monitoring of liver and kidney function during MDR-TB treatment is necessary to monitor patient condition.

THE LIVER FUNCTION TEST (TRANSAMINASE ENZYMES AND BILIRUBIN) AND THE KIDNEY FUNCTION TESTS (UREA, CREATININE) ANALYSIS IN MDR-TB DURING TREATMENT . (2026). INDONESIAN JOURNAL OF HEALTH SCIENCES RESEARCH AND DEVELOPMENT (IJHSRD), 8(1), 109-114. https://doi.org/10.36566/ijhsrd/Vol8.Iss1/370
Download data is not yet available.
  1. 1. World Health Organization. 2024 Global Tuberculosis (TB) Report. 2024. 8 p.
  2. 2. Gao W, Wang W, Li J, Gao Y, Zhang S, Lei H, et al. Drug-resistance characteristics, genetic diversity, and transmission dynamics of multidrug-resistant or rifampicin-resistant Mycobacterium tuberculosis from 2019 to 2021 in Sichuan, China. Antimicrob Resist Infect Control. 2024;13(1).
  3. 3. Song HW, Tian JH, Song HP, Guo SJ, Lin YH, Pan JS. Tracking multidrug resistant tuberculosis: a 30-year analysis of global, regional, and national trends. Front Public Heal. 2024;12(1).
  4. 4. Omoteso OA, Fadaka AO, Walker RB, Khamanga SM. Innovative Strategies for Combating Multidrug-Resistant Tuberculosis: Advances in Drug Delivery Systems and Treatment. Microorganisms. 2025;13(4):1–42.
  5. 5. Chandra B, Fikriana R, Nurbadriyah WD. Faktor Risiko pada Peningkatan Kasus Multidrug-Resistant Tuberculosis ( MDR-TB ) di Indonesia : Tinjauan Literatur. J Univ Muhammadiyah Surabaya. 2025;10(1):159–67.
  6. 6. Xi Y, Zhang W, Qiao RJ, Tang J. Risk factors for multidrug-resistant tuberculosis: A worldwide systematic review and meta-analysis. PLoS One. 2022;17(6 June):1–15.
  7. 7. Muhammad Gugun A, Suryanto S, Ranti Ayuningtyas DN. The Effect of Initial Anti-tuberculosis Drug Therapy on Transminase Enzymes. Cerdika J Ilm Indones. 2024;4(03):214–21.
  8. 8. Muda I, Adam MF, Saputra R, Muhyi A, Noprianto D, Aminuddin M. Association of Multidrug-Resistant Tuberculosis (MDR-TB) Patients on Profile of Liver and Kidney Function. J Kesehat Pasak Bumi Kalimantan. 2023;5(2):139.
  9. 9. Osorio-chávez JS, González VP, Ferraz-amaro I, Castañeda S, Manuel J, Martínez C, et al. Hepatotoxicity Risk of Isoniazid in Patients with Autoimmune Rheumatic Diseases and Prior Liver Injury Due to Disease-Modifying Antirheumatic Drugs : A Single-Center Experience and Literature Review. 2026;1–13.
  10. 10. Sharma K, Basith KMA, Subramanian S, Chinnakali P, Rajaram M, Basu S, et al. Abnormal Liver Function at the Time of Tuberculosis Diagnosis in South India. 2026;
  11. 11. Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis an Off Publ Infect Dis Soc Am. 2016 Oct;63(7):853–67.
  12. 12. Aprianto, Sudarsono TA, Pratiwi D, Wardani K. Comparison of Ureum and Creatinine Levels Pulmonary Tuberculosis in. J Ilmu dan Teknol Kesehat. 2022;9(2).
  13. 13. Saito N, Yoshii Y, Kaneko Y, Nakashima A, Horikiri T, Saito Z, et al. Impact of renal function-based anti- tuberculosis drug dosage adjustment on efficacy and safety outcomes in pulmonary tuberculosis complicated with chronic kidney disease. 2019;1–8.
  14. 14. Park S, Kim HW, Lee EG, Park Y, Jung SS, Woo J, et al. BMC Infectious Diseases Article in Press Association between reduced kidney function and tuberculosis treatment outcomes. 2026.

Copyright (c) 2026 INDONESIAN JOURNAL OF HEALTH SCIENCES RESEARCH AND DEVELOPMENT (IJHSRD)

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Copyright Rights & Permissions Guide

Reproducing Published Material from other Publishers

It is absolutely essential that authors obtain permission to reproduce any published material (figures, schemes, tables or any extract of a text) which does not fall into the public domain, or for which they do not hold the copyright. Permission should be requested by the authors from the copyright holder (usually the Publisher, please refer to the imprint of the individual publications to identify the copyright holder).

Permission is required for:

  1. Your own works published by other Publishers and for which you did not retain copyright.
  2. Substantial extracts from anyones’ works or a series of works.
  3. Use of Tables, Graphs, Charts, Schemes and Artworks if they are unaltered or slightly modified.
  4. Photographs for which you do not hold copyright.

Permission is not required for:

  1. Reconstruction of your own table with data already published elsewhere. Please notice that in this case you must cite the source of the data in the form of either “Data from…” or “Adapted from…”.
  2. Reasonably short quotes are considered fair use and therefore do not require permission.
  3. Graphs, Charts, Schemes and Artworks that are completely redrawn by the authors and significantly changed beyond recognition do not require permission.

Obtaining Permission

In order to avoid unnecessary delays in the publication process, you should start obtaining permissions as early as possible. If in any doubt about the copyright, apply for permission. JNH cannot publish material from other publications without permission.

The copyright holder may give you instructions on the form of acknowledgement to be followed; otherwise follow the style: “Reproduced with permission from [author], [book/journal title]; published by [publisher], [year].’ at the end of the caption of the Table, Figure or Scheme.

Every mansucript should be accompanied by "Copyright Transfer Agreement" prior to the article publication

Dimension Badge

Downloads

Downloads
Crossmark Badge
Crossmark Badge
Section
Articles
Keywords
Multi Drug Resistance Tuberculosis Liver function Kidney Function

Similar Articles

11-20 of 32

You may also start an advanced similarity search for this article.